(object) array( 'id' => '3951142', 'url' => 'FR/Yawning-No-More', 'image' => 'yawning.jpg; bush yawning.jpg;', 'title' => 'Yawning-No-More', 'tags' => array ( 0 => 'Yawning-No-More', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Yawning-No-More', 'source_id' => 639288, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721084108', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un nouveau médicament de relaxation musculaire qui stoppe les bâillements pendant un certain nombre d\'heures. Le bâillement est une réaction allergique du corps à cause de la fatigue, du manque de stimulation, ou de l\'ennui. Yawning-No-More détend les muscles qui induisent le bâillement ainsi la personne peut éviter de bâiller jusqu\'à cinq heures. Le bâillement peut être gênant lors de rassemblements sociaux ou des réunions d\'affaires car il peut montrer un manque d\'intérêt ou d\'énergie. Ce nouveau médicament promet de changer sensiblement la façon dont la société voit le bâillement.', 'usage_comment' => '', 'glossary' => '', 'width' => 503, 'height' => 340, '_version_' => 1507294573051772928, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Yawning-No-More', 'Definition' => 'A new muscle relaxation drug that stops yawning for a number of hours. Yawing is an allergic reaction of the body due to tiredness, lack of stimulation, or boredom. Yawning-No-More relaxes the muscles that induce yawning so the person can be spared of yawning for up to five hours. Yawning can be embarrassing during social gatherings or business meetings as it may show a lack of interests or energy. This new drug promises to substantially change the way society views yawning.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Sample Image' => 'yawning.jpg; bush yawning.jpg;', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Creation User' => 'BruceLH', 'Creation Date' => '2011/1/23', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Yawning-No-More', )

(object) array( 'id' => '6228625', 'url' => 'FR/publications_₂', 'image' => '', 'title' => 'Publications', 'tags' => array ( 0 => 'Publications', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Publications', 'source_id' => 4011325, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722110603', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Articles ou résumés scientifiques publiés concernant une étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507394292251885568, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'Published scientific articles or abstracts about a clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'publications', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'publications_₂', )

(object) array( 'id' => '3898056', 'url' => 'FR/variable_ratio_₁', 'image' => '', 'title' => 'Proportion variable', 'tags' => array ( 0 => 'Proportion variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Proportion variable', 'source_id' => 3744260, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105908', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => '1) Un programme de renforcement basé sur la réponse dans lequel le nombre de réponses requises pour un renforcement varie après que chaque renforçateur est présenté. Le nombre moyen de réponses est utilisé pour indexer le programme. Par exemple, un rat peut appuyer sur un levier de renforcement 50 fois, puis 150, 70, 30, et 200. En ajoutant ces besoins de réponse pour un total de 500, puis en divisant par le nombre de réponses distinctes apportées (5), on obtient la valeur du programme, PV 100. 2) Un programme dans lequel une personne est renforcée en effectuant une réponse seulement après avoir effectué un nombre variable de ces réponses sans renforcement. Ce programme induit généralement un rythme élevé et uniforme. Il produit le plus haut rythme de réponses pour les programmes simples.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851744059393, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => '1) A response-based schedule of reinforcement in which the number of responses required for reinforcement changes after each reinforcer is presented. The average number of responses is used to index the schedule. For example, a rat may press a lever for reinforcement 50 times, then 150, 70, 30, and 200. Adding these response requirements for a total of 500, then dividing by the number of separate response runs (5), yields the schedule value, VR 100. 2) A schedule in which people are reinforced for making a response only after they have made a varying number of those responses without reinforcement. This schedule usually causes people to work at a high and uniform rate of speed. It produces the highest rate of responding of the simple schedules.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'See Also' => 'ratio schedules of reinforcement_₀', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable ratio', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable_ratio_₁', )

(object) array( 'id' => '6229325', 'url' => 'FR/informed_consent_₁₂', 'image' => '', 'title' => 'Consentement éclairé', 'tags' => array ( 0 => 'Consentement éclairé', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Consentement éclairé', 'source_id' => 4011444, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104711', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un processus dans lequel les chercheurs communiquent avec les participants potentiels et inscrits dans une étude clinique. Ceci est lorsque les chercheurs : # fournissent toutes les informations importantes concernant l\'étude, de sorte que les participants potentiels peuvent décider de s\'y inscrire (ou si elles sont inscrites, de continuer à participer) ; # s\'assurent que les participants potentiels comprennent les risques et les bénéfices potentiels de participer à l\'étude, et les alternatives à l\'étude conduite ; et # soulignent que l\'inscription à une étude clinique (et de rester dedans) est entièrement volontaire. Parce que donner son consentement pour participer à la recherche n\'est pas un contrat, les participants peuvent quitter une étude à tout moment. Le but du processus de consentement éclairé est de protéger les participants. Il commence quand un participant potentiel demande au début des informations sur une étude et continue tout au long de l\'étude jusqu\'à ce que l\'étude se termine. Le chercheur et le participant potentiel ont des discussions qui incluent de répondre aux questions des participants sur la recherche. Toutes les informations importantes à propos de l\'étude doivent également être remises au participant potentiel dans un document écrit qui est clair et facile à comprendre. Ce document de consentement éclairé est examiné et approuvé par le Comité de protection des personnes pour chaque étude avant d\'être remis aux participants potentiels. Généralement, une personne doit signer un document de consentement éclairé pour s\'inscrire dans une étude.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431490, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A process in which researchers communicate with potential and enrolled participants about a clinical study. This is when researchers: # provide all the important information about the study, so that potential participants can decide whether to enroll (or if enrolled, to continue participating); # ensure that potential participants understand the risks and potential benefits of participating in the study, and the alternatives to the research being conducted; and # stress that enrolling in (and staying in) a clinical study is completely voluntary. Because giving consent to participate in research is not a contract, participants can leave a study at any time. The goal of the informed consent process is to protect participants. It begins when a potential participant first asks for information about a study and continues throughout the study until the study ends. The researcher and potential participant have discussions that include answering the participant\'s questions about the research. All the important information about the study must also be given to the potential participant in a written document that is clear and easy to understand. This informed consent document is reviewed and approved by the human subjects review board for a study before it is given to potential participants. Generally, a person must sign an informed consent document to enroll in a study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'informed consent', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'informed_consent_₁₂', )

(object) array( 'id' => '3897820', 'url' => 'FR/variable-interval_₁', 'image' => '', 'title' => 'Intervalle variable', 'tags' => array ( 0 => 'Intervalle variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle variable', 'source_id' => 3744241, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105901', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un renforçateur dépend de la première réponse après un intervalle de temps variable depuis la dernière opportunité pour un renforcement.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851727282176, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'A reinforcer is contingent on the first response after a variable interval of time since the last opportunity for reinforcement.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable-interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable-interval_₁', )

(object) array( 'id' => '8442002', 'url' => 'FR/thiomersal', 'image' => 'Vaccines with thiomersal.jpg;', 'title' => 'Thiomersal', 'tags' => array ( 0 => 'Thiomersal', 1 => 'Pharmaceutical', 2 => 'Vaccines', 3 => '', ), 'term' => 'Thiomersal', 'source_id' => 274263, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Vaccines', ), 'lastedit' => '20150721084102', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le thimérosal est un conservateur contenant du mercure qui est souvent utilisé dans les vaccins en raison de ses propriétés antiseptiques et antifongiques. L\'utilisation du thimérosal comme conservateur de vaccin a été controversée au cours des dernières années en raison du risque potentiellement accru de provoquer l\'autisme chez les enfants. Cependant, la dernière étude du CDC a toutefois montré qu\'aucun lien n\'avait été trouvé entre le thimérosal et l\'autisme.', 'usage_comment' => '', 'glossary' => '', 'width' => 485, 'height' => 385, '_version_' => 1507294573052821508, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'thiomersal', 'Definition' => 'Thimerosal is a mercury-based preservative that is often used in vaccines because of its antiseptic and antifungal properties. The use of thimerosal as a vaccine preservative has been controversial in recent years due to potentially increased risk of causing children\'s autism. However, the latest CDC study however showed no link found between thimerosal and autism', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Synonym' => '', 'Sample Image' => 'Vaccines with thiomersal.jpg;', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Vaccines', 'Domain' => 'Documentation; Marketing', 'Other Reference' => 'TIN', 'Creation User' => 'Williamb', 'Creation Date' => '2010/9/13', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'thiomersal', )

(object) array( 'id' => '6228059', 'url' => 'FR/single_blind_masking', 'image' => '', 'title' => 'Etude en simple aveugle', 'tags' => array ( 0 => 'Etude en simple aveugle', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Etude en simple aveugle', 'source_id' => 4011054, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105915', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un type d\'étude en aveugle dans laquelle une partie impliquée dans l\'essai clinique, soit l\'investigateur soit le participant, ne sait pas à quels participants ont été assignées quelles interventions.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107970, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A type of masking in which one party involved with the clinical trial, either the investigator or participant, does not know which participants have been assigned which interventions.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'single blind masking', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'single_blind_masking', )

(object) array( 'id' => '6229090', 'url' => 'FR/comparison_group_₂', 'image' => '', 'title' => 'Groupe de comparaison', 'tags' => array ( 0 => 'Groupe de comparaison', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Groupe de comparaison', 'source_id' => 4011326, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104707', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un groupe de participants à une étude clinique qui est utilisé pour synthétiser les données recueillies lors de l\'étude. Ce groupe peut être identique ou différent d\'un bras de l\'étude.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431488, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A grouping of participants in a clinical study that is used in summarizing the data collected during the study. This grouping may be the same as or different from a study arm.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Synonym' => 'reporting_group', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'comparison group', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'comparison_group_₂', )

(object) array( 'id' => '6229990', 'url' => 'FR/other_adverse_event', 'image' => '', 'title' => 'Autre événement indésirable', 'tags' => array ( 0 => 'Autre événement indésirable', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Autre événement indésirable', 'source_id' => 4011599, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722110608', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un événement indésirable qui n\'est pas un événement indésirable grave.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507394292252934144, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'An adverse event that is not a serious adverse event.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'other adverse event', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'other_adverse_event', )

(object) array( 'id' => '3898054', 'url' => 'FR/fixed-interval_₁', 'image' => '', 'title' => 'Intervalle fixe', 'tags' => array ( 0 => 'Intervalle fixe', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle fixe', 'source_id' => 3744252, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105905', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Programme de renforcement. Un renforçateur dépend de la première réponse après un intervalle de temps fixe depuis la dernière opportunité pour un renforcement.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851728330753, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'schedule of reinforcement. A reinforcer is contingent on the first response after a fixed interval of time since the last opportunity for reinforcement.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'fixed-interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'fixed-interval_₁', )